Treatment Avenues for Age-Related Macular Degeneration: Breakthroughs and Bottlenecks
Popat Kumbhar,Kaustubh Kolekar,Sukriti Vishwas,Priya Shetti,Vijay Kumbar,Terezinha de Jesus Andreoli Pinto,Ana Cláudia Paiva-Santos,Francisco Veiga,Guarav Gupta,Sachin Kumar Singh,Kamal Dua,John Disouza,Vandana Patravale
DOI: https://doi.org/10.1016/j.arr.2024.102322
IF: 11.788
2024-05-09
Ageing Research Reviews
Abstract:Age-related macular degeneration (AMD) is a significant factor contributing to serious vision loss in adults above 50. The presence of posterior segment barriers serves as chief roadblocks in the delivery of drugs to treat AMD. The conventional treatment strategies use is limited due to its off-targeted distribution in the eye, shorter drug residence, poor penetration and bioavailability, fatal side effects, etc. The above-mentioned downside necessitates drug delivery using some cutting-edge technology including diverse nanoparticulate systems and microneedles (MNs) which provide the best therapeutic delivery alternative to treat AMD efficiently. Furthermore, cutting-edge treatment modalities including gene therapy and stem cell therapy can control AMD effectively by reducing the boundaries of conventional therapies with a single dose. This review discusses AMD overview, conventional therapies for AMD and their restrictions, repurposed therapeutics and their anti-AMD activity through different mechanisms, and diverse barriers in drug delivery for AMD. Various nanoparticulate-based approaches including polymeric NPs, lipidic NPs, exosomes, active targeted NPs, stimuli-sensitive NPs, cell membrane-coated NPs, inorganic NPs, and MNs are explained. Gene therapy, stem cell therapy, and therapies in clinical trials to treat AMD are also discussed. Further, bottlenecks of cutting-edge (nanoparticulate) technology-based drug delivery are briefed. In a nutshell, cutting-edge technology-based therapies can be an effective way to treat AMD.
cell biology,geriatrics & gerontology,gerontology